Vaughn M Louette, Waller Edmund K
Center for Transfusion and Cellular Therapies, Emory University Hospital, Atlanta, GA, USA.
Methods Mol Biol. 2012;904:79-83. doi: 10.1007/978-1-61779-943-3_6.
Hematopoietic Progenitor Cell (HPC) Apheresis generally results in a mononuclear cell product that is highly enriched for hematopoietic stem and progenitor cells when performed on autologous patients in whom autologous stem cell transplant is planned who have been mobilized with cytotoxic chemotherapy and exogenous hematopoietic growth factors (cytokines) and possibly CXCR4 antagonists. Alternatively, patients scheduled for autologous transplants may be mobilized with cytokines only or a combination of cytokines and CXCR4 antagonists. Allogeneic Donors, either matched related donors (MRD) or matched unrelated donors (MUD), are typically mobilized with cytokines only. The HPC Apheresis product, enriched for hematopoietic progenitor cells collected from the patient/donor's peripheral blood via an apheresis system, is used for restoring hematopoiesis in the patient/recipient who has received myeloablative therapy. Timing of the collection of an HPC Apheresis product from allogeneic donors is based on the schedule of the recipient's myeloablative regime. However, the optimal timing of collection on HPC Apheresis product from a patient scheduled for an autologous stem cell transplant can be complex.
造血祖细胞（HPC）单采术通常会产生一种单核细胞产品，当对计划进行自体干细胞移植且已通过细胞毒性化疗、外源性造血生长因子（细胞因子）以及可能的CXCR4拮抗剂进行动员的自体患者进行该操作时，该产品会高度富集造血干细胞和祖细胞。或者，计划进行自体移植的患者可以仅用细胞因子或细胞因子与CXCR4拮抗剂的组合进行动员。同种异体供体，无论是匹配的相关供体（MRD）还是匹配的无关供体（MUD），通常仅用细胞因子进行动员。通过单采系统从患者/供体外周血中采集的富含造血祖细胞的HPC单采产品，用于在接受清髓性治疗的患者/受者中恢复造血功能。从同种异体供体采集HPC单采产品的时间基于受者清髓方案的时间表。然而，对于计划进行自体干细胞移植的患者，采集HPC单采产品的最佳时间可能很复杂。
